Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

This study has been completed.
Eli Lilly and Company
Department of Defense
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: September 26, 2011
Last updated: August 10, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2015
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)